Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Muscular Dystrophy, Duchenne

Treatments: Genetic: PF-06939926

Study type: Interventional

Funder types: Industry

Identifiers

NCT05429372

C3391008

2021-003379-33 (EudraCT Number)

Details and patient eligibility

About

The study will evaluate the safety and dystrophin expression following gene therapy in boys with Duchenne Muscular Dystrophy (DMD). It is a single-arm, non-randomized, open-label study

Full description

The study will assess the safety and tolerability of fordadistrogene movaparvovec gene therapy. Approximately 10 participants will be enrolled in the study and receive a single IV infusion of PF-06939926; there is no placebo arm. The study includes boys who are at least 2 years old and less than 4 years old (including 3 year olds up until their 4th birthday). All boys will need to be negative for neutralizing antibodies against AAV9, as measured by the test done for the study as part of screening.

The primary analysis will occur when all participants have completed visits through Week 52 (or withdrawn from the study prior to Week 52). All participants will be followed in the study for 5 years after treatment with gene therapy.

Enrollment: 10 patients

Sex: Male

Ages: 2 to 3 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Confirmed diagnosis of DMD by prior genetic testing.

Exclusion criteria

• Any of the following genetic abnormalities in the dystrophin gene: a. Any mutation (exon deletion, exon duplication, insertion, or point mutation) affecting any exon between exon 9 and exon 13, inclusive; OR b. A deletion that affects both exon 29 and exon 30; OR c. A deletion that affects any exons between 56-71, inclusive.
• Positive test performed by Pfizer for neutralizing antibodies to AAV9.
• Any prior treatment with gene therapy.
• Any treatment designed to increase dystrophin expression within 6 months prior to screening (including, but not limited to, exon-skipping and nonsense read through).
• Previous or current treatment with oral glucocorticoids or other immunosuppressive agents for the indication of DMD.
• Abnormality in specified laboratory tests, including blood counts, liver and kidney function.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

PF-06939926

Experimental group

Treatment:

Genetic: PF-06939926